Halozyme appoints Jim Daly to board of directors

• Halozyme appointed James “Jim” Daly to its board of directors.
• Daly was Incyte’s executive vice president and chief commercial officer from 2012 to 2015.
• He previously spent a decade at Amgen, most recently as senior vice president for North America commercial operations, global marketing, commercial development.
• Earlier, Daly spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including senior vice president and general manager of the U.S. respiratory business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA59857) on September 30, 2026, and is solely responsible for the information contained therein.